ZA200308520B - Anthranilac acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds. - Google Patents
Anthranilac acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds. Download PDFInfo
- Publication number
- ZA200308520B ZA200308520B ZA200308520A ZA200308520A ZA200308520B ZA 200308520 B ZA200308520 B ZA 200308520B ZA 200308520 A ZA200308520 A ZA 200308520A ZA 200308520 A ZA200308520 A ZA 200308520A ZA 200308520 B ZA200308520 B ZA 200308520B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbon atoms
- heteroaryl
- alkyl
- naphthyl
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 27
- 239000003814 drug Substances 0.000 title claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 title description 2
- 238000000034 method Methods 0.000 title description 2
- 150000001408 amides Chemical class 0.000 title 1
- 239000000032 diagnostic agent Substances 0.000 title 1
- 229940039227 diagnostic agent Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims description 145
- -1 dimethylamino, sulfamoyl Chemical group 0.000 claims description 106
- 125000000217 alkyl group Chemical group 0.000 claims description 102
- 125000001072 heteroaryl group Chemical group 0.000 claims description 98
- 125000001624 naphthyl group Chemical group 0.000 claims description 93
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 93
- 229910052739 hydrogen Inorganic materials 0.000 claims description 84
- 239000001257 hydrogen Substances 0.000 claims description 84
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 75
- 150000002431 hydrogen Chemical class 0.000 claims description 66
- 125000001424 substituent group Chemical group 0.000 claims description 63
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 41
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 30
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 28
- 125000001041 indolyl group Chemical group 0.000 claims description 28
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 28
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 28
- 125000005493 quinolyl group Chemical group 0.000 claims description 28
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 28
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 27
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 27
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 27
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 26
- 125000004076 pyridyl group Chemical group 0.000 claims description 26
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 25
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 71
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 16
- 238000011321 prophylaxis Methods 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 230000036982 action potential Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10128331A DE10128331A1 (de) | 2001-06-12 | 2001-06-12 | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200308520B true ZA200308520B (en) | 2004-09-06 |
Family
ID=7687941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200308520A ZA200308520B (en) | 2001-06-12 | 2003-10-31 | Anthranilac acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds. |
Country Status (40)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| US7119112B2 (en) * | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
| BR0309522A (pt) * | 2002-04-26 | 2005-02-09 | Ishihara Sangyo Kaisha | Compostos piridina ou sais destes e herbicidas contendo os mesmos |
| EP1388535A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| DE10312061A1 (de) * | 2003-03-18 | 2004-09-30 | Aventis Pharma Deutschland Gmbh | Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien |
| GB0315950D0 (en) | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
| EP1489071A1 (en) * | 2003-06-18 | 2004-12-22 | 4Sc Ag | N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators |
| SI1651621T1 (sl) | 2003-08-08 | 2008-12-31 | Janssen Pharmaceutica Nv | 2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2 |
| DE10341233A1 (de) * | 2003-09-08 | 2005-03-24 | Aventis Pharma Deutschland Gmbh | Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien |
| DE102004009931A1 (de) * | 2004-02-26 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| US7569589B2 (en) | 2004-07-29 | 2009-08-04 | Merck & Co., Inc. | Potassium channel inhibitors |
| CA2581426A1 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
| US7576212B2 (en) | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
| GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
| RU2436577C2 (ru) * | 2006-04-27 | 2011-12-20 | Санофи-Авентис Дойчланд Гмбх | Ингибиторы ионных task-1 и task-3 каналов |
| WO2008124524A2 (en) * | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Aryl sulfonamide compounds as modulators of the cck2 receptor |
| GB0815782D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815781D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815784D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| CA2765611A1 (en) * | 2009-06-29 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane |
| RU2561132C2 (ru) * | 2009-06-29 | 2015-08-20 | Аджиос Фармасьютикалз, Инк. | Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности |
| WO2011010132A1 (en) * | 2009-07-21 | 2011-01-27 | Astrazeneca Ab | Sustained-release composition comprising compound 600 |
| RU2414893C1 (ru) * | 2009-11-11 | 2011-03-27 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Четвертичное аммониевое производное новокаина, обладающее противоаритмической активностью, и способ его получения |
| FR2967674B1 (fr) * | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| US20150045305A1 (en) | 2012-01-27 | 2015-02-12 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| US9701627B2 (en) * | 2014-06-16 | 2017-07-11 | University Of Maryland, Baltimore | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders |
| WO2019031472A1 (ja) * | 2017-08-07 | 2019-02-14 | 国立大学法人広島大学 | 新規アントラニル酸系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0686625B1 (en) | 1993-12-27 | 1999-05-26 | Eisai Co., Ltd. | Anthranilic acid derivative |
| US5670504A (en) | 1995-02-23 | 1997-09-23 | Merck & Co. Inc. | 2,6-diaryl pyridazinones with immunosuppressant activity |
| US6083986A (en) | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
| DK173062B1 (da) | 1996-10-11 | 1999-12-13 | Krueger As I | Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto |
| US5969017A (en) | 1996-10-31 | 1999-10-19 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| US5935945A (en) | 1996-10-31 | 1999-08-10 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| CN1332943C (zh) * | 1998-07-08 | 2007-08-22 | 萨诺费－阿文蒂斯德国有限公司 | 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂 |
| AU754204B2 (en) * | 1998-09-01 | 2002-11-07 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
| MXPA02000123A (es) * | 1999-06-24 | 2002-07-02 | Smithkline Beecham Corp | Antagonistas de receptor depurador de macrofago. |
| DE19947457A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
| US6531495B1 (en) | 1999-10-02 | 2003-03-11 | Aventis Pharma Deutschland Gmbh | 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
-
2001
- 2001-06-12 DE DE10128331A patent/DE10128331A1/de not_active Withdrawn
-
2002
- 2002-05-17 PE PE2002000419A patent/PE20021066A1/es not_active Application Discontinuation
- 2002-05-21 OA OA1200300333A patent/OA12631A/fr unknown
- 2002-05-31 JP JP2003503594A patent/JP4422477B2/ja not_active Expired - Fee Related
- 2002-05-31 IL IL15924702A patent/IL159247A0/xx unknown
- 2002-05-31 ES ES02745333T patent/ES2295360T3/es not_active Expired - Lifetime
- 2002-05-31 RU RU2004100302/04A patent/RU2293727C2/ru not_active IP Right Cessation
- 2002-05-31 AU AU2002316939A patent/AU2002316939B2/en not_active Ceased
- 2002-05-31 KR KR1020037016206A patent/KR100863924B1/ko not_active Expired - Fee Related
- 2002-05-31 PL PL02364371A patent/PL364371A1/xx not_active IP Right Cessation
- 2002-05-31 SK SK1522-2003A patent/SK15222003A3/sk unknown
- 2002-05-31 NZ NZ530081A patent/NZ530081A/en unknown
- 2002-05-31 BR BR0210374-5A patent/BR0210374A/pt not_active Application Discontinuation
- 2002-05-31 WO PCT/EP2002/005956 patent/WO2002100825A2/de not_active Ceased
- 2002-05-31 HR HR20031028A patent/HRP20031028A2/hr not_active Application Discontinuation
- 2002-05-31 MX MXPA03010875A patent/MXPA03010875A/es active IP Right Grant
- 2002-05-31 AT AT02745333T patent/ATE378318T1/de active
- 2002-05-31 CA CA2450076A patent/CA2450076C/en not_active Expired - Fee Related
- 2002-05-31 CZ CZ20033361A patent/CZ20033361A3/cs unknown
- 2002-05-31 DE DE50211213T patent/DE50211213D1/de not_active Expired - Lifetime
- 2002-05-31 DK DK02745333T patent/DK1399423T3/da active
- 2002-05-31 EP EP02745333A patent/EP1399423B9/de not_active Expired - Lifetime
- 2002-05-31 HU HU0400159A patent/HUP0400159A3/hu unknown
- 2002-05-31 EE EEP200300558A patent/EE05196B1/xx not_active IP Right Cessation
- 2002-05-31 CN CNB028118502A patent/CN1247544C/zh not_active Expired - Fee Related
- 2002-05-31 UA UA2004010206A patent/UA75412C2/uk unknown
- 2002-05-31 RS YU97703A patent/RS97703A/sr unknown
- 2002-05-31 PT PT02745333T patent/PT1399423E/pt unknown
- 2002-06-10 AR ARP020102178A patent/AR036045A1/es active IP Right Grant
- 2002-06-10 TW TW091112464A patent/TWI304400B/zh not_active IP Right Cessation
- 2002-06-11 MY MYPI20022165A patent/MY138341A/en unknown
- 2002-06-12 US US10/166,595 patent/US6903216B2/en not_active Expired - Lifetime
-
2003
- 2003-07-08 TN TNPCT/EP2002/005956A patent/TNSN03134A1/en unknown
- 2003-10-31 ZA ZA200308520A patent/ZA200308520B/en unknown
- 2003-11-04 CR CR7140A patent/CR7140A/es not_active Application Discontinuation
- 2003-12-03 EC EC2003004883A patent/ECSP034883A/es unknown
- 2003-12-04 BG BG108415A patent/BG108415A/xx unknown
- 2003-12-08 IL IL159247A patent/IL159247A/en not_active IP Right Cessation
- 2003-12-08 NO NO20035450A patent/NO20035450D0/no not_active Application Discontinuation
- 2003-12-10 MA MA27434A patent/MA27037A1/fr unknown
- 2003-12-11 CO CO03108701A patent/CO5540283A2/es not_active Application Discontinuation
-
2005
- 2005-02-08 US US11/052,959 patent/US7235664B2/en not_active Expired - Lifetime
-
2008
- 2008-02-04 CY CY20081100143T patent/CY1107427T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200308520B (en) | Anthranilac acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds. | |
| CA2445341A1 (en) | Anthranilamides, process for their preparation, their use as antiarrhythmics, and pharmaceutical preparations thereof | |
| JP2004533464A5 (https=) | ||
| BRPI0011324B8 (pt) | agonistas de adrenoceptores beta 2, processo de preparação dos mesmos, seu uso e composição farmacêutica compreendendo os mesmos | |
| CA2476065A1 (en) | Inhibitors of histone deacetylase | |
| NZ515282A (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
| SK282721B6 (sk) | Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| HUP0303317A2 (hu) | Orto, meta-szubsztituált biszarilszármazékok, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| JP2007516983A5 (https=) | ||
| CA2446326A1 (en) | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| CO5280070A1 (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular | |
| JP2016506387A5 (https=) | ||
| BR0308696A (pt) | Derivados de quinolina e seu emprego como ligante de 5-ht6 | |
| WO1993021919A1 (en) | Hydroxypyridin-4-ones for treatment of parasitical infections | |
| HRP20020264B1 (hr) | 2'-supstituirani 1,1'-bifenil-2-karbonamidi, postupci za njihovu proizvodnju, njihova upotreba kao lijeka, kao i farmaceutski pripravci koji ih sadrže | |
| JPWO2023095860A5 (https=) | ||
| JP2004525178A5 (https=) | ||
| HU0301173D0 (en) | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme | |
| IL160082A0 (en) | Quinoline derivatives and use thereof as antitumor agents | |
| RU2205829C2 (ru) | Замещенное производное циклобутиламина, антибактериальный агент и фармацевтическая композиция на его основе | |
| KR100785148B1 (ko) | 20-ｈｅｔｅ 생산 효소 저해제 | |
| JPS61180785A (ja) | 新規な治療用組成物 | |
| US4117131A (en) | Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides | |
| CA2355716A1 (en) | Benzisoxazoles and phenones as .alpha.2-antagonists |